Development of bone mineral density in patients using progestogen-only contraceptivesOriginal contributions

L. Bortlík, M. Bužga, V. Šmajstrla, S. Čuboková

Clin Osteol 2012; 17(4): 123-127

Aim of study: Measurement of bone mineral density (BMD) by DXA in women using progestogen-only contraceptives (depot medro­ xyprogesterone acetate - DMPA, Depo-Provera injections, Pfizer Inc.). Material and methods: In DMPA users, BMD was reassessed after at least three years of use. All the women were premenopau­ sal. BMD was measured by the Hologic W DXA densitometer in the lumbar spine, total femur and femur neck. BMD and Z-score were evaluated. Results: Out of 116 DMPA users, 44 could be invited for the reassessment. The mean length of use of DMPA was 8.1 years (range, 3.5 to 12.1 years). No significant changes in BMD in any of the measured skeletal...

Limited walking ability significantly contributes to a loss of bone mineral density in the proximal femur in premenopausal and postmenopausal women with multiple sclerosisReview articles

I. Raška jr., M. Týblová, M. Rašková, D. Michalská, E. Havrdová, V. Zikán

Clin Osteol 2012; 17(4): 128-135

The aim of the study was to assess changes in bone mineral density (BMD) in relation to VDR gene polymorphisms (Bsm-I and Fok-I), motor deficit and glucocorticoid treatment in multiple sclerosis (MS) patients without osteoporosis supplemented with vitamin D and calcium and MS patients with osteoporosis treated with risedronate. A total of 165 women treated with low-dose glucocorticoids without osteoporosis and 34 patients with newly diagnosed osteoporosis and newly treated with risedronate were included in this lon­ gitudinal study. The Expanded Disability Status Scale (EDSS) score was less than 6.5 in all patients. After 2-year observation, women...

Solitary bone plasmacytomaReview articles

T. Pika, J. Minařík, V. Prášil, H. Crháková, J. Bačovský, V. Ščudla

Clin Osteol 2012; 17(4): 136-142

Solitary bone plasmacytoma (SBP) is a relatively uncommon entity from the group of monoclonal gammopathies. This is a solitary skeletal lesion made of monoclonal plasma cell populations, associated with bone involvement. Manifestation of the condition is fre­ quently associated with impaired function of the axial skeleton, neurological deficit and tenderness. Less frequently, this is a randomly detected asymptomatic bone lesion. The diagnosis is often complicated, requiring collaboration of many medical experts. If the dia­ gnosis of SBP is confirmed, the treatment modality is radiotherapy or, in case of structural instability or neurological involvement,...

Role of biological therapy for osteoporosis in rheumatoid arthritisReview articles

J. Rovenský, P. Masaryk

Clin Osteol 2012; 17(4): 143-149

Rheumatoid arthritis (RA) is a frequent, severe inflammatoryjoint disease affecting all age groups, with the peak incidence in young people and premenopausal women. The causes of the disease are multifactorial, including certain genetic predispositions. It is cha­ racterized by chronic inflammation initiated and maintained by autoimmune mechanisms. The course of RA is rather variable. Acute exacerbations may alternate with periods of remission. Generally, however, the course is progressive, frequently leading to disability The disease may shorten life by tens of years. Rheumatoid arthritis is a heterogeneous disease, with varied disease activity as...

Calcimimetics in the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD): current knowledge, new information and future prospectsReview articles

S. Dusilová Sulková

Clin Osteol 2012; 17(4): 150-159

Calcimimetics (cinacalcet hydrochloride) modulate the calcium-sensing receptor (CaR). The effect means not only suppression of pa­ rathormone secretion but also inhibition of parathyroid activity and growth. Since 2004 (a bit later in the C has been available for the treatment of secondary hyperparathyroidism (SHPT) in patients with kidney failure. Secondary hyperparathyroidism is a unifying moment of chronic kidney disease-mineral and bone disorder (CKD-MBD). The article is concerned with the effect of calcimimetics on individual CKD-MBD components (laboratory, bone and vascular). Large and long-term studies are available, including those from the...

News from around the worldLiterature

Clin Osteol 2012; 17(4): 160-163